Mito-LND
Based on 3 publication(s) in Google Scholar
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 97.0%
- CAS 番号: 2361564-49-8
- 分子式: C43H45BrCl2N3OP
- 分子量:801.62
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-112037
IACS-010759OXPHOS Inhibitor -
HY-100410
FCCPOXPHOS Uncoupler -
HY-111651
GboxinOXPHOS Inhibitor -
HY-134539
IMT1POLRMT Inhibitor -
HY-12406
VLX600OXPHOS Inhibitor/Iron Chelator -
HY-16772
EPI-743Vitamin E Analog -
HY-135231
NL-1MitoNEET Inhibitor -
HY-N0105
RheinAntioxidant -
HY-N1441
AfzelinFlavonol Glycoside -
HY-N6882
Genistein 8-c-glucosideApoptosis Inducer -
HY-N0105R
Rhein (Standard) -
HY-N4202
DihydrorotenoneApoptosis Inducer/Insecticide
MedChemExpress（MCE）の使用を引用している文献 Mito-LND
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.69 μM
Compound: Mito-LND
|
Antiproliferative activity against human A549 cells by IncuCyte live-cell imaging assay
Antiproliferative activity against human A549 cells by IncuCyte live-cell imaging assay
|
[PMID: 33103432] |
| A549 | IC50 |
0.69 μM
Compound: 33; Mito-LND
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 36893622] |
| NSCLC | ED50 |
7.5 μmol/Kg
Compound: 33; Mito-LND
|
Antitumor activity against human NSCLC cells xenografted in orthotopic lung tumor mouse model assessed as reduction in tumor growth incubated for 8 weeks
Antitumor activity against human NSCLC cells xenografted in orthotopic lung tumor mouse model assessed as reduction in tumor growth incubated for 8 weeks
|
[PMID: 36893622] |
| NSCLC | IC50 |
0.74 μM
Compound: 33; Mito-LND
|
Antiproliferative activity against human NSCLC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human NSCLC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 36893622] |
体外実験
Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 μM and 0.69 μM, respectively[1].
Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 μM and 2.4 μM, respectively in H2030BrM3 cells[1].
Mito-LND (1 μM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells[1].
Mito-LND (2 μM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
Mito-LND also decreases the rate of growth of A549 tumor xenografts[1].
Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic nude mice (5 weeks) injected with H2030BrM3 cells[1]
-
Dosage:7.5 µmol/kg
-
Administration:Oral gavage; 5 days per week; for 3 consecutive weeks
-
Result:Significantly decreased tumor progression.
化学情報
-
CAS 番号 2361564-49-8
-
性状 Solid
-
分子量 801.62
-
分子式 C43H45BrCl2N3OP
-
Color Off-white to light yellow
-
SMILES
O=C(NCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=NN(CC5=CC=C(Cl)C=C5Cl)C6=C4C=CC=C6.[Br-]
-
別名
Mito-Lonidamine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Tumor-intrinsic redox programming drives an SPP1-CD44 axis of immune suppression in uveal melanoma. [Abstract]2026 Mar:90:104011. PMID: 41534302 -
J Transl Med
Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma. [Abstract]2024 Aug 28;22(1):792. PMID: 39198815 -
J Transl Med
Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment. [Abstract]2023 Aug 7;21(1):532. PMID: 37550679
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (62.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2475 mL | 6.2374 mL | 12.4747 mL | 31.1868 mL |
| 5 mM | 0.2495 mL | 1.2475 mL | 2.4949 mL | 6.2374 mL | |
| 10 mM | 0.1247 mL | 0.6237 mL | 1.2475 mL | 3.1187 mL | |
| 15 mM | 0.0832 mL | 0.4158 mL | 0.8316 mL | 2.0791 mL | |
| 20 mM | 0.0624 mL | 0.3119 mL | 0.6237 mL | 1.5593 mL | |
| 25 mM | 0.0499 mL | 0.2495 mL | 0.4990 mL | 1.2475 mL | |
| 30 mM | 0.0416 mL | 0.2079 mL | 0.4158 mL | 1.0396 mL | |
| 40 mM | 0.0312 mL | 0.1559 mL | 0.3119 mL | 0.7797 mL | |
| 50 mM | 0.0249 mL | 0.1247 mL | 0.2495 mL | 0.6237 mL | |
| 60 mM | 0.0208 mL | 0.1040 mL | 0.2079 mL | 0.5198 mL |
Mito-LND 関連分類
HY-134832 関連分類
Powered by Bioz